Literature DB >> 19776239

Involvement of the Fc gamma receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection.

Meng Ling Moi1, Chang-Kweng Lim, Tomohiko Takasaki, Ichiro Kurane.   

Abstract

Sub-neutralizing concentrations of antibody to dengue virus (DENV) enhance DENV infection of Fc gamma receptor-expressing cells. This phenomenon, referred to as antibody-dependent enhancement (ADE), has been hypothesized to be responsible for the severe form of DENV infection, including dengue haemorrhagic fever and dengue shock syndrome. To analyse further the mechanisms of ADE in vitro, this study introduced a series of cytoplasmic mutants into human Fc gammaRIIA. The mutated Fc gammaRIIA was then expressed on COS-7 cells to see whether these mutants could enhance DENV infection. Wild-type Fc gammaRIIA enhanced DENV infection, consistent with previous reports using Fc gammaR-positive monocytes. Disruption of the immune tyrosine activation motif (ITAM) in the cytoplasmic domain of Fc gammaRIIA or removing the sequences between the two ITAM regions eliminated ADE. These findings suggest that the specific structure of the Fc gammaRIIA cytoplasmic domain is essential for the ability of Fc gammaRIIA to mediate ADE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776239     DOI: 10.1099/vir.0.014829-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.

Authors:  Kobporn Boonnak; Kaitlyn M Dambach; Gina C Donofrio; Boonrat Tassaneetrithep; Mary A Marovich
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

Review 2.  Antibody-mediated neutralization of flaviviruses: a reductionist view.

Authors:  Kimberly A Dowd; Theodore C Pierson
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

3.  Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism.

Authors:  Gissel García; Beatriz Sierra; Ana B Pérez; Eglys Aguirre; Ileana Rosado; Narjara Gonzalez; Alienys Izquierdo; Maritza Pupo; Didye Ruiz Danay Díaz; Lizet Sánchez; Beatriz Marcheco; Kenji Hirayama; María G Guzmán
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

4.  Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.

Authors:  Kobporn Boonnak; Bonnie M Slike; Gina C Donofrio; Mary A Marovich
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

Review 5.  Dengue vaccines: recent developments, ongoing challenges and current candidates.

Authors:  Monica A McArthur; Marcelo B Sztein; Robert Edelman
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

6.  Association of FcγRIIa Polymorphism with Clinical Outcome of Dengue Infection: First Insight from Pakistan.

Authors:  Saima Naz Mohsin; Saqib Mahmood; Ali Amar; Farkhanda Ghafoor; Syed Mohsin Raza; Mahjabeen Saleem
Journal:  Am J Trop Med Hyg       Date:  2015-08-03       Impact factor: 2.345

7.  Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcgamma receptor (FcgammaR)-negative and FcgammaR-expressing BHK-21 cells.

Authors:  Meng Ling Moi; Chang-Kweng Lim; Akira Kotaki; Tomohiko Takasaki; Ichiro Kurane
Journal:  Clin Vaccine Immunol       Date:  2009-12-30

Review 8.  Innate immune receptors drive dengue virus immune activation and disease.

Authors:  Joris Sprokholt; Leanne C Helgers; Teunis Bh Geijtenbeek
Journal:  Future Virol       Date:  2017-11-17       Impact factor: 1.831

Review 9.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

10.  Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse.

Authors:  Naphak Modhiran; Siripen Kalayanarooj; Sukathida Ubol
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.